14 results on '"Tenforde, Mark W"'
Search Results
2. Author response for 'Ascertainment of vaccination status by self-report versus source documentation: Impact on measuring COVID-19 vaccine effectiveness'
- Author
-
null Stephenson, Meagan, null Olson, Samantha M., null Self, Wesley H., null Ginde, Adit A., null Mohr, Nicholas M., null Gaglani, Manjusha, null Shapiro, Nathan, I, null Gibbs, Kevin W., null Hager, David N., null Prekker, Matthew E., null Gong, Michelle N., null Steingrub, Jay S., null Peltan, Ithan D., null Martin, Emily T., null Reddy, Raju, null Busse, Laurence W., null Duggal, Abhijit, null Wilson, Jennifer G., null Qadir, Nida, null Mallow, Christopher, null Kwon, Jennie H., null Exline, Matthew C., null Chappell, James D., null Lauring, Adam S., null Baughman, Adrienne, null Lindsell, Christopher J., null Hart, Kimberly W., null Lewis, Nathaniel M., null Patel, Manish M., and null Tenforde, Mark W.
- Published
- 2022
3. Exposures in adult outpatients with COVID‐19 infection during early community transmission, Tennessee
- Author
-
Tenforde, Mark W., Feldstein, Leora R., Lindsell, Christopher J., Patel, Manish M., Self, Wesley H., Keipp Talbot, H., Grijalva, Carlos G., Rice, Todd W., Baughman, Adrienne H., McClellan, Robert, Wang, Li, Hart, Kimberly W., Shapiro, Nathan I., Kassem, Ahmed M., Sciarratta, Courtney N., Dzuris, Nicole, Griggs, Eric P., Smith, Emily R., Ogokeh, Constance E., Wu, Michael, Kim, Sara S., Marcet, Paula L., and Siddula, Akshita
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Epidemiology ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Letter to the Editors ,law.invention ,law ,Outpatients ,Humans ,Medicine ,Letter to the Editor ,SARS-CoV-2 ,business.industry ,Public Health, Environmental and Occupational Health ,COVID-19 ,Middle Aged ,Tennessee ,Virology ,Cross-Sectional Studies ,Infectious Diseases ,Transmission (mechanics) ,Female ,business - Published
- 2020
4. Symptoms and recovery among adult outpatients with and without COVID‐19 at 11 healthcare facilities—July 2020, United States
- Author
-
Fisher, Kiva A., primary, Olson, Samantha M., additional, Tenforde, Mark W., additional, Self, Wesley H., additional, Wu, Michael, additional, Lindsell, Christopher J., additional, Shapiro, Nathan I., additional, Files, D. Clark, additional, Gibbs, Kevin W., additional, Erickson, Heidi L., additional, Prekker, Matthew E., additional, Steingrub, Jay S., additional, Exline, Matthew C., additional, Henning, Daniel J., additional, Wilson, Jennifer G., additional, Brown, Samuel M., additional, Peltan, Ithan D., additional, Rice, Todd W., additional, Hager, David N., additional, Ginde, Adit A., additional, Talbot, H. Keipp, additional, Casey, Jonathan D., additional, Grijalva, Carlos G., additional, Flannery, Brendan, additional, Patel, Manish M., additional, Feldstein, Leora R., additional, Hart, Kimberly W., additional, McClellan, Robert, additional, Tan, Hsi‐nien, additional, Baughman, Adrienne, additional, Hennesy, Nora A., additional, Grear, Brittany, additional, Mlynarczyk, Kristin, additional, Marzano, Luc, additional, Plata, Zuwena, additional, Caplan, Alexis, additional, Ogokeh, Constance E., additional, Smith, Emily R., additional, Kim, Sara S., additional, Griggs, Eric P., additional, Richards, Bridget, additional, Robinson, Sonya, additional, Kim, Kaylee, additional, Kassem, Ahmed M., additional, Sciarratta, Courtney N., additional, and Marcet, Paula L., additional
- Published
- 2021
- Full Text
- View/download PDF
5. Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis
- Author
-
Tenforde, Mark W, Gertz, Alida M, Lawrence, David S, Wills, Nicola K, Guthrie, Brandon L, Farquhar, Carey, and Jarvis, Joseph N
- Abstract
INTRODUCTION: HIV-associated cryptococcal, TB and pneumococcal meningitis are the leading causes of adult meningitis in sub-Saharan Africa (SSA). We performed a systematic review and meta-analysis with the primary aim of estimating mortality from major causes of adult meningitis in routine care settings, and to contrast this with outcomes from clinical trial settings. METHODS: We searched PubMed, EMBASE and the Cochrane Library for published clinical trials (defined as randomized-controlled trials (RCTs) or investigator-managed prospective cohorts) and observational studies that evaluated outcomes of adult meningitis in SSA from 1 January 1990 through 15 September 2019. We performed random effects modelling to estimate pooled mortality, both in clinical trial and routine care settings. Outcomes were stratified as short-term (in-hospital or two weeks), medium-term (up to 10 weeks) and long-term (up to six months). RESULTS AND DISCUSSION: Seventy-nine studies met inclusion criteria. In routine care settings, pooled short-term mortality from cryptococcal meningitis was 44% (95% confidence interval (95% CI):39% to 49%, 40 studies), which did not differ between amphotericin (either alone or with fluconazole) and fluconazole-based induction regimens, and was twofold higher than pooled mortality in clinical trials using amphotericin based treatment (21% (95% CI:17% to 25%), 17 studies). Pooled short-term mortality of TB meningitis was 46% (95% CI: 33% to 59%, 11 studies, all routine care). For pneumococcal meningitis, pooled short-term mortality was 54% in routine care settings (95% CI:44% to 64%, nine studies), with similar mortality reported in two included randomized-controlled trials. Few studies evaluated long-term outcomes. CONCLUSIONS: Mortality rates from HIV-associated meningitis in SSA are very high under routine care conditions. Better strategies are needed to reduce mortality from HIV-associated meningitis in the region.
- Published
- 2020
6. Treatment for HIV-associated cryptococcal meningitis
- Author
-
Tenforde, Mark W, Shapiro, Adrienne E, Rouse, Benjamin, Jarvis, Joseph N, Li, Tianjing, Eshun-Wilson, Ingrid, and Ford, Nathan
- Abstract
BACKGROUND: Cryptococcal meningitis is a severe fungal infection that occurs primarily in the setting of advanced immunodeficiency and remains a major cause of HIV-related deaths worldwide. The best induction therapy to reduce mortality from HIV-associated cryptococcal meningitis is unclear, particularly in resource-limited settings where management of drug-related toxicities associated with more potent antifungal drugs is a challenge. OBJECTIVES: To evaluate the best induction therapy to reduce mortality from HIV-associated cryptococcal meningitis; to compare side effect profiles of different therapies. SEARCH METHODS: We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE (PubMed), Embase (Ovid), LILACS (BIREME), African Index Medicus, and Index Medicus for the South-East Asia Region (IMSEAR) from 1 January 1980 to 9 July 2018. We also searched the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), ClinicalTrials.gov, and the ISRCTN registry; and abstracts of select conferences published between 1 July 2014 and 9 July 2018. SELECTION CRITERIA: We included randomized controlled trials that compared antifungal induction therapies used for the first episode of HIV-associated cryptococcal meningitis. Comparisons could include different individual or combination therapies, or the same antifungal therapies with differing durations of induction (less than two weeks or two or more weeks, the latter being the current standard of care). We included data regardless of age, geographical region, or drug dosage. We specified no language restriction. DATA COLLECTION AND ANALYSIS: Two review authors independently screened titles and abstracts identified by the search strategy. We obtained the full texts of potentially eligible studies to assess eligibility and extracted data using standardized forms. The main outcomes included mortality at 2 weeks, 10 weeks, and 6 months; mean rate of cerebrospinal fluid fungal clearance in the first two weeks of treatment; and Division of AIDS (DAIDS) grade three or four laboratory events. Using random-effects models we determined pooled risk ratio (RR) and 95% confidence interval (CI) for dichotomous outcomes and mean differences (MD) and 95% CI for continuous outcomes. For the direct comparison of 10-week mortality, we assessed the certainty of the evidence using the GRADE approach. We performed a network meta-analysis using multivariate meta-regression. We modelled treatment differences (RR and 95% CI) and determined treatment rankings for two-week and 10-week mortality outcomes using surface under the cumulative ranking curve (SUCRA). We assessed transitivity by comparing distribution of effect modifiers between studies, local inconsistency through a node-splitting approach, and global inconsistency using design-by-treatment interaction modelling. For the network meta-analysis, we applied a modified GRADE approach for assessing the certainty of the evidence for 10-week mortality. MAIN RESULTS: We included 13 eligible studies that enrolled 2426 participants and compared 21 interventions. All studies were carried out in adults, and all but two studies were conducted in resource-limited settings, including 11 of 12 studies with 10-week mortality data.In the direct pairwise comparisons evaluating 10-week mortality, one study from four sub-Saharan African countries contributed data to several key comparisons. At 10 weeks these data showed that those on the regimen of one-week amphotericin B deoxycholate (AmBd) and flucytosine (5FC) followed by fluconazole (FLU) on days 8 to 14 had lower mortality when compared to (i) two weeks of AmBd and 5FC (RR 0.62, 95% CI 0.42 to 0.93; 228 participants, 1 study), (ii) two weeks of AmBd and FLU (RR 0.58, 95% CI 0.39 to 0.86; 227 participants, 1 study), (iii) one week of AmBd with two weeks of FLU (RR 0.49, 95% CI 0.34 to 0.72; 224 participants, 1 study), and (iv) two weeks of 5FC and FLU (RR 0.68, 95% CI 0.47 to 0.99; 338 participants, 1 study). The evidence for each of these comparisons was of moderate certainty. For other outcomes, this shortened one-week AmBd and 5FC regimen had similar fungal clearance (MD 0.05 log10 CFU/mL/day, 95% CI -0.02 to 0.12; 186 participants, 1 study) as well as lower risk of grade three or four anaemia (RR 0.31, 95% CI 0.16 to 0.60; 228 participants, 1 study) compared to the two-week regimen of AmBd and 5FC.For 10-week mortality, the comparison of two weeks of 5FC and FLU with two weeks of AmBd and 5FC (RR 0.92, 95% CI 0.69 to 1.23; 340 participants, 1 study) or two weeks of AmBd and FLU (RR 0.85, 95% CI 0.64 to 1.13; 339 participants, 1 study) did not show a difference in mortality, with moderate-certainty evidence for both comparisons.When two weeks of combination AmBd and 5FC was compared with AmBd alone, pooled data showed lower mortality at 10 weeks (RR 0.66, 95% CI 0.46 to 0.95; 231 participants, 2 studies, moderate-certainty evidence).When two weeks of AmBd and FLU was compared to AmBd alone, there was no difference in 10-week mortality in pooled data (RR 0.94, 95% CI 0.55 to 1.62; 371 participants, 3 studies, low-certainty evidence).One week of AmBd and 5FC followed by FLU on days 8 to 14 was the best induction therapy regimen after comparison with 11 other regimens for 10-week mortality in the network meta-analysis, with an overall SUCRA ranking of 88%. AUTHORS' CONCLUSIONS: In resource-limited settings, one-week AmBd- and 5FC-based therapy is probably superior to other regimens for treatment of HIV-associated cryptococcal meningitis. An all-oral regimen of two weeks 5FC and FLU may be an alternative in settings where AmBd is unavailable or intravenous therapy cannot be safely administered. We found no mortality benefit of combination two weeks AmBd and FLU compared to AmBd alone. Given the absence of data from studies in children, and limited data from high-income countries, our findings provide limited guidance for treatment in these patients and settings.
- Published
- 2018
7. India Ink Stain and Cryptococcal Antigen Test for Cryptococcal Infection
- Author
-
Mitchell, Hannah K., primary, Jarvis, Joseph N., additional, and Tenforde, Mark W., additional
- Published
- 2019
- Full Text
- View/download PDF
8. Treatment for HIV-associated cryptococcal meningitis
- Author
-
Tenforde, Mark W, primary, Shapiro, Adrienne E, additional, Rouse, Benjamin, additional, Jarvis, Joseph N, additional, Li, Tianjing, additional, Eshun-Wilson, Ingrid, additional, and Ford, Nathan, additional
- Published
- 2018
- Full Text
- View/download PDF
9. Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders.
- Author
-
Levy ME, Yang DH, Dunne MM, Miley K, Irving SA, Grannis SJ, Weber ZA, Griggs EP, Spark TL, Bassett E, Embi PJ, Gaglani M, Natarajan K, Valvi NR, Ong TC, Naleway AL, Stenehjem E, Klein NP, Link-Gelles R, DeSilva MB, Kharbanda AB, Raiyani C, Beaton MA, Dixon BE, Rao S, Dascomb K, Patel P, Mamawala M, Han J, Fadel WF, Barron MA, Grisel N, Dickerson M, Liao IC, Arndorfer J, Najdowski M, Murthy K, Ray C, Tenforde MW, and Ball SW
- Subjects
- Adult, Humans, COVID-19 Vaccines, Retrospective Studies, Vaccination, Hospitalization, RNA, Messenger, COVID-19 epidemiology, COVID-19 prevention & control, Mental Disorders epidemiology
- Abstract
Background: Although psychiatric disorders have been associated with reduced immune responses to other vaccines, it remains unknown whether they influence COVID-19 vaccine effectiveness (VE). This study evaluated risk of COVID-19 hospitalization and estimated mRNA VE stratified by psychiatric disorder status., Methods: In a retrospective cohort analysis of the VISION Network in four US states, the rate of laboratory-confirmed COVID-19-associated hospitalization between December 2021 and August 2022 was compared across psychiatric diagnoses and by monovalent mRNA COVID-19 vaccination status using Cox proportional hazards regression., Results: Among 2,436,999 adults, 22.1% had ≥1 psychiatric disorder. The incidence of COVID-19-associated hospitalization was higher among patients with any versus no psychiatric disorder (394 vs. 156 per 100,000 person-years, p < 0.001). Any psychiatric disorder (adjusted hazard ratio [aHR], 1.27; 95% CI, 1.18-1.37) and mood (aHR, 1.25; 95% CI, 1.15-1.36), anxiety (aHR, 1.33, 95% CI, 1.22-1.45), and psychotic (aHR, 1.41; 95% CI, 1.14-1.74) disorders were each significant independent predictors of hospitalization. Among patients with any psychiatric disorder, aHRs for the association between vaccination and hospitalization were 0.35 (95% CI, 0.25-0.49) after a recent second dose, 0.08 (95% CI, 0.06-0.11) after a recent third dose, and 0.33 (95% CI, 0.17-0.66) after a recent fourth dose, compared to unvaccinated patients. Corresponding VE estimates were 65%, 92%, and 67%, respectively, and were similar among patients with no psychiatric disorder (68%, 92%, and 79%)., Conclusion: Psychiatric disorders were associated with increased risk of COVID-19-associated hospitalization. However, mRNA vaccination provided similar protection regardless of psychiatric disorder status, highlighting its benefit for individuals with psychiatric disorders., (© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
10. An updated systematic review of HIV-associated cryptococcal meningitis treatment strategies.
- Author
-
Shapiro AE, Tenforde MW, Chiller TM, Ford N, and Rajasingham R
- Subjects
- Humans, Amphotericin B therapeutic use, Amphotericin B adverse effects, Flucytosine therapeutic use, Flucytosine adverse effects, Fluconazole therapeutic use, Antifungal Agents therapeutic use, Drug Therapy, Combination, Randomized Controlled Trials as Topic, Meningitis, Cryptococcal drug therapy, HIV Infections complications, HIV Infections drug therapy
- Abstract
Background: The purpose of this systematic review is to provide updated evidence on the preferred induction therapy for the treatment of HIV-associated cryptococcal meningitis considering the most recent evidence available in order to inform the need for updates to WHO guidelines., Methods: We searched Medline via PubMed, EMBASE, the Cochrane Library and clinicaltrials.gov for published or completed randomized clinical trials that evaluated induction treatment of first episode HIV-associated cryptococcal meningitis from 9 July 2018 (date of last search) to 1 September 2021., Results: One randomized clinical trial of 844 people with HIV-associated cryptococcal meningitis met the inclusion criteria. Participants were randomized to: (1) amphotericin deoxycholate for 7 days, with flucytosine and fluconazole (control); or (2) a single dose of liposomal amphotericin 10 mg/kg with flucytosine and fluconazole (intervention). In the intention-to-treat analysis, 10-week mortality was 24.8% [95% confidence interval (CI): 20.7-29.3%] in the single-dose liposomal amphotericin group compared with 28.7% (95% CI: 24.4-33.4%) in the control group. The absolute difference in 10-week mortality was -3.9% with an upper one-sided 95% CI of 1.2%, within the 10% pre-specified non-inferiority margin. Fewer participants had grade 3 and 4 adverse events in the intervention arm compared with the control arm (50.0% vs. 62.3%, p < 0.001)., Conclusions: In the single study included in this systematic review, single high-dose liposomal amphotericin B with flucytosine and fluconazole was non-inferior to the WHO-recommended standard of care induction therapy for HIV-associated cryptococcal meningitis, with significantly fewer adverse events., (© 2022 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.)
- Published
- 2023
- Full Text
- View/download PDF
11. Ascertainment of vaccination status by self-report versus source documentation: Impact on measuring COVID-19 vaccine effectiveness.
- Author
-
Stephenson M, Olson SM, Self WH, Ginde AA, Mohr NM, Gaglani M, Shapiro NI, Gibbs KW, Hager DN, Prekker ME, Gong MN, Steingrub JS, Peltan ID, Martin ET, Reddy R, Busse LW, Duggal A, Wilson JG, Qadir N, Mallow C, Kwon JH, Exline MC, Chappell JD, Lauring AS, Baughman A, Lindsell CJ, Hart KW, Lewis NM, Patel MM, and Tenforde MW
- Subjects
- Adult, Documentation, Humans, Pandemics, RNA, Messenger, SARS-CoV-2, Self Report, Vaccination, Vaccine Efficacy, COVID-19 epidemiology, COVID-19 prevention & control, COVID-19 Vaccines
- Abstract
Background: During the COVID-19 pandemic, self-reported COVID-19 vaccination might facilitate rapid evaluations of vaccine effectiveness (VE) when source documentation (e.g., immunization information systems [IIS]) is not readily available. We evaluated the concordance of COVID-19 vaccination status ascertained by self-report versus source documentation and its impact on VE estimates., Methods: Hospitalized adults (≥18 years) admitted to 18 U.S. medical centers March-June 2021 were enrolled, including COVID-19 cases and SARS-CoV-2 negative controls. Patients were interviewed about COVID-19 vaccination. Abstractors simultaneously searched IIS, medical records, and other sources for vaccination information. To compare vaccination status by self-report and documentation, we estimated percent agreement and unweighted kappa with 95% confidence intervals (CIs). We then calculated VE in preventing COVID-19 hospitalization of full vaccination (2 doses of mRNA product ≥14 days prior to illness onset) independently using data from self-report or source documentation., Results: Of 2520 patients, 594 (24%) did not have self-reported vaccination information to assign vaccination group; these patients tended to be more severely ill. Among 1924 patients with both self-report and source documentation information, 95.0% (95% CI: 93.9-95.9%) agreement was observed, with a kappa of 0.9127 (95% CI: 0.9109-0.9145). VE was 86% (95% CI: 81-90%) by self-report data only and 85% (95% CI: 81-89%) by source documentation data only., Conclusions: Approximately one-quarter of hospitalized patients could not provide self-report COVID-19 vaccination status. Among patients with self-report information, there was high concordance with source documented status. Self-report may be a reasonable source of COVID-19 vaccination information for timely VE assessment for public health action., (© 2022 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.)
- Published
- 2022
- Full Text
- View/download PDF
12. Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021-February 2022.
- Author
-
Kim SS, Chung JR, Talbot HK, Grijalva CG, Wernli KJ, Kiniry E, Martin ET, Monto AS, Belongia EA, McLean HQ, Gaglani M, Mamawala M, Nowalk MP, Moehling Geffel K, Tartof SY, Florea A, Lee JS, Tenforde MW, Patel MM, Flannery B, Bentz ML, Burgin A, Burroughs M, Davis ML, Howard D, Lacek K, Madden JC, Nobles S, Padilla J, and Sheth M
- Subjects
- Adult, Humans, COVID-19 Testing, COVID-19 Vaccines, SARS-CoV-2 genetics, RNA, Messenger genetics, Outpatients, COVID-19 prevention & control
- Abstract
Background: We estimated SARS-CoV-2 Delta- and Omicron-specific effectiveness of two and three mRNA COVID-19 vaccine doses in adults against symptomatic illness in US outpatient settings., Methods: Between October 1, 2021, and February 12, 2022, research staff consented and enrolled eligible participants who had fever, cough, or loss of taste or smell and sought outpatient medical care or clinical SARS-CoV-2 testing within 10 days of illness onset. Using the test-negative design, we compared the odds of receiving two or three mRNA COVID-19 vaccine doses among SARS-CoV-2 cases versus controls using logistic regression. Regression models were adjusted for study site, age, onset week, and prior SARS-CoV-2 infection. Vaccine effectiveness (VE) was calculated as (1 - adjusted odds ratio) × 100%., Results: Among 3847 participants included for analysis, 574 (32%) of 1775 tested positive for SARS-CoV-2 during the Delta predominant period and 1006 (56%) of 1794 participants tested positive during the Omicron predominant period. When Delta predominated, VE against symptomatic illness in outpatient settings was 63% (95% CI: 51% to 72%) among mRNA two-dose recipients and 96% (95% CI: 93% to 98%) for three-dose recipients. When Omicron predominated, VE was 21% (95% CI: -6% to 41%) among two-dose recipients and 62% (95% CI: 48% to 72%) among three-dose recipients., Conclusions: In this adult population, three mRNA COVID-19 vaccine doses provided substantial protection against symptomatic illness in outpatient settings when the Omicron variant became the predominant cause of COVID-19 in the United States. These findings support the recommendation for a third mRNA COVID-19 vaccine dose., Competing Interests: Ana Florea reports unrelated institutional grant support for research from Gilead, GlaxoSmithKline, Moderna, and Pfizer. Carlos G. Grijalva reports consulting fees from Merck, Pfizer, and Sanofi Pasteur, and institutional grant support from the Agency for Health Care Research and Quality, Campbell Alliance/Syneos Health, the Food and Drug Administration, and the National Institutes of Health. Emily T. Martin reports institutional grant support from Merck. Arnold S. Monto reports personal fees from Sanofi and non‐financial support from Seqirus. Mary Patricia Nowalk reports unrelated institutional grant support and personal fees from Merck Sharp & Dohme and institutional investigator‐initiated grant support from Sanofi Pasteur. Sara Y. Tartof reports unrelated institutional grant support from Pfizer and GlaxoSmithKline. No other potential conflicts of interest were disclosed., (Published 2022. This article is a U.S. Government work and is in the public domain in the USA. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
13. Associations between persistent symptoms after mild COVID-19 and long-term health status, quality of life, and psychological distress.
- Author
-
Han JH, Womack KN, Tenforde MW, Files DC, Gibbs KW, Shapiro NI, Prekker ME, Erickson HL, Steingrub JS, Qadir N, Khan A, Hough CL, Johnson NJ, Ely EW, Rice TW, Casey JD, Lindsell CJ, Gong MN, Srinivasan V, Lewis NM, Patel MM, and Self WH
- Subjects
- Adult, Health Status, Humans, Prospective Studies, Quality of Life psychology, SARS-CoV-2, Post-Acute COVID-19 Syndrome, COVID-19 complications, COVID-19 epidemiology, Psychological Distress
- Abstract
Background: We sought to assess whether persistent COVID-19 symptoms beyond 6 months (Long-COVID) among patients with mild COVID-19 is associated with poorer health status, quality of life, and psychological distress., Methods: This was a multicenter prospective cohort study that included adult outpatients with acute COVID-19 from eight sites during 2-week sampling periods from April 1 and July 28, 2020. Participants were contacted 6-11 months after their first positive SARS-CoV-2 to complete a survey, which collected information on the severity of eight COVID-19 symptoms using a 4-point scale ranging from 0 (not present) to 3 (severe) at 1 month before COVID-19 (pre-illness) and at follow-up; the difference for each was calculated as an attributable persistent symptom severity score. A total attributable persistent COVID-19 symptom burden score was calculated by summing the attributable persistent severity scores for all eight symptoms. Outcomes measured at long-term follow-up comprised overall health status (EuroQol visual analogue scale), quality of life (EQ-5D-5L), and psychological distress (Patient Health Questionnaire-4). The association between the total attributable persistent COVID-19 burden score and each outcome was analyzed using multivariable proportional odds regression., Results: Of the 2092 outpatients with COVID-19, 436 (21%) responded to the survey. The median (IQR) attributable persistent COVID-19 symptom burden score was 2 (0, 4); higher scores were associated with lower overall health status (aOR 0.63; 95% CI: 0.57-0.69), lower quality of life (aOR: 0.65; 95%CI: 0.59-0.72), and higher psychological distress (aOR: 1.40; 95%CI, 1.28-1.54) after adjusting for age, race, ethnicity, education, and income., Conclusions: In participants with mild acute COVID-19, the burden of persistent symptoms was significantly associated with poorer long-term health status, poorer quality of life, and psychological distress., (© 2022 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.)
- Published
- 2022
- Full Text
- View/download PDF
14. Exposures in adult outpatients with COVID-19 infection during early community transmission, Tennessee.
- Author
-
Tenforde MW, Feldstein LR, Lindsell CJ, Patel MM, and Self WH
- Subjects
- Adult, COVID-19 epidemiology, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Outpatients, Tennessee epidemiology, COVID-19 transmission, SARS-CoV-2
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.